Komunikaty PR

Asthma and COPD Drugs Market 2025: Strategic Insights for Growth, Expansion, and Gaining Competitive Edge

2025-07-04  |  13:55:06
The Business Research Company

The Business Research Company

The Business Research Company's Asthma and COPD Drugs Market 2025: Strategic Insights for Growth, Expansion, and Gaining Competitive Edge

It will grow to $50.99 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%.”
— The Business Research Company

LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 /EINPresswire.com/ -- Save 30% on all global market reports with code ONLINE30 – stay informed on tariff changes, macroeconomic trends, and more.

The asthma and chronic obstructive pulmonary disease COPD drugs market has witnessed significant growth in recent years. It is projected to rise from $32.52 billion in 2024 to $35.66 billion in 2025, reflecting a compound annual growth rate CAGR of 9.6%. This robust growth during the historical period can be attributed to escalating air pollution levels, rising incidence of tobacco smoking, increasing awareness about respiratory diseases, growing adoption of corticosteroids and bronchodilators, and escalating healthcare expenditure.

What Is The Future Growth Potential Of The Asthma And COPD Drugs Market?
The asthma and chronic obstructive pulmonary disease COPD drugs market is poised for remarkable growth in the forthcoming years, with projections putting it at $50.99 billion by 2029 at a CAGR of 9.4%. This anticipated growth during the forecast period can be attributed to the growing demand for personalized medicine, increasing adoption of biologics and advanced therapies, rising incidence of environmental allergies, increasing clinical trials and approvals, and the growing burden of non-communicable diseases. Key trends emerging during the forecast period include technology-enabled smart inhalers, developing dual-acting bronchodilators, integration of electronic health records EHR and drug data, innovations in biopharmaceutical molecules, and the integration of machine learning in drug discovery.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp

What Are The Key Driving Forces For The Growth Of The Asthma and COPD Drugs Market?
A critical propellant for the growth of the asthma and COPD drugs market is the increasing prevalence of smoking. Smoking, which involves the habit of consuming tobacco products by inhaling the smoke, can lead to grave health issues such as lung cancer and heart disease. The mounting prevalence of smoking, driven primarily by social influence where peer pressure, cultural norms, and social environments entice individuals to start and continue smoking, has a direct bearing on the growth of the asthma and COPD drugs market. These drugs mitigate the respiratory damage caused by smoking through reducing inflammation, relaxing airway muscles, and improving airflow, thereby alleviating symptoms and enhancing lung function.

Who Are The Key Industry Players In The Asthma And COPD Drugs Market?
The asthma and chronic obstructive pulmonary disease COPD drugs market arena is teeming with major players such as Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd. Roche, Merck & Co. Inc., Sanofi, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc GSK, Eli Lilly and Company, Amgen, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma, AptarGroup, Chiesi Farmaceutici S.p.A., Dr. Reddy’s Laboratories, Cipla Inc., Lupin Limited, Zydus Cadila, Glenmark Pharmaceuticals, Vectura Group, Aurobindo Pharma.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/asthma-and-chronic-obstructive-pulmonary-disease-copd-drugs-global-market-report

What Are The Emerging Trends In The Asthma And COPD Drugs Market?
Major players in the asthma and COPD drugs market are putting their focus on developing innovative formulations. For instance, they are creating fixed-dose combination FDC drugs. These single dosage forms contain two or more active ingredients and help manage asthma and COPD by combining bronchodilators and anti-inflammatories to improve symptom control and patient adherence.

How Is The Asthma And COPD Drugs Market Segmented?
The asthma and chronic obstructive pulmonary disease COPD drugs market delineated in this report is segmented by various attributes:
1 By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers
2 By Route Of Administration: Inhalation, Oral, Injection, Nasal, Other Route Of Administrations
3 By Patient Group: Adult, Pediatric, Geriatric
4 By Application: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Pulmonary Hypertension
5 By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Furthermore, there are subsegments:
1 By Bronchodilators: Short-Acting Beta-2 Agonists SABA, Long-Acting Beta-2 Agonists LABA, Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines
2 By Corticosteroids: Inhaled Corticosteroids ICS, Oral Corticosteroids, Intravenous Corticosteroids
3 By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid
4 By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors

What Are The Regional Insights Into The Asthma And COPD Drugs Market?
In 2024, North America was the largest region in the asthma and COPD drugs market. However, in the forecast period, Asia-Pacific is expected to register the fastest growth. The regions covered in the report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:
Asthma Spacers Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/asthma-spacers-global-market-report
Anti-Asthmatics And COPD Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report
Inhaled Antibiotics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/inhaled-antibiotics-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info


Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 7882 955267
info|tbrc.info| |info|tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, firmy czy instytucje państwowe.
Ostatnio dodane
komunikaty PR z wybranej przez Ciebie kategorii
EIN Newswire BRAK ZDJĘCIA
2025-07-06 | 11:55:05

Helvetic Clinics bestätigt europäische Marktführerschaft im Zahntourismus mit 20 % Wachstum im ersten Halbjahr 2025

Helvetic Clinics, Best dental clinic in HungaryDental Clinic BudapestHelvetic Clinics, von Experten als beste Zahnklinik im Ausland anerkannt, verzeichnet im ersten Halbjahr 2025 ein Wachstum von 20 % bei der Zahl der Patienten.BUDAPEST,
EIN Newswire BRAK ZDJĘCIA
2025-07-06 | 08:55:09

Technical Review: leagend BA2001 Battery Tester for Lead-Acid and LiFePO₄ Batteries

leagend BA2001leagend battery testersleagendThis article provides a detailed overview of leagend BA2001’s technical capabilities and highlights its position within leagend’s broader Battery Testers. NEW YORK, NY, UNITED STATES, July 6, 2025
EIN Newswire BRAK ZDJĘCIA
2025-07-06 | 03:55:05

Medical Supplierz Expands Services to Support Bulk Clinic Procurement

Bulk buying transforms clinics’ efficiency and fuels our global vision. We’re creating scalable solutions that drive savings, market reach, and value for medical institutions of all kinds”— Bader Alajeel, CEO of Medical

Więcej ważnych informacji

Jedynka Newserii

Jedynka Newserii

Kongres Profesjonalistów Public Relations

Bankowość

Rośnie liczba i wartość udzielonych konsumentom kredytów gotówkowych. Gorzej mają się kredyty ratalne oraz te udzielane firmom

Rynek kredytowy w Polsce co do zasady rośnie, choć nierównomiernie. Z danych Biura Informacji Kredytowej wynika, że najlepiej rozwija się segment kredytów gotówkowych dla konsumentów. Wartościowo wzrosła też kwota udzielonych limitów w kartach kredytowych. Według prognoz BIK w całym roku wzrośnie wartość zarówno udzielonych kredytów mieszkaniowych, jak i gotówkowych, choć tych pierwszych poniżej inflacji. Wcześniejsze cięcia stóp procentowych przez RPP nie zmieniły tej prognozy.

Transport

37,5 proc. środków z Planu Społeczno-Klimatycznego trafi na walkę z ubóstwem transportowym. Organizacje branżowe apelują o zmianę priorytetowych projektów [DEPESZA]

Ministerstwo Funduszy i Polityki Regionalnej z końcem czerwca zakończyło konsultacje Planu Społeczno-Klimatycznego, który otwiera drogę do pozyskania 65 mld zł (11,4 mld euro) z unijnego Społecznego Funduszu Klimatycznego. Polska będzie jego największym beneficjentem, a 37,5 proc. budżetu zostanie przeznaczone na bezpośrednie wsparcie osób narażonych na ubóstwo transportowe. Organizacje branżowe oceniają jednak, że walka z tym zjawiskiem może się okazać nieskuteczna. W toku konsultacji zgłosiły swoje zastrzeżenia co do priorytetów w wydatkach i sposobu wsparcia inwestycji w transport rowerowy.

Prawo

Firmy będą mogły przetestować krótszy tydzień pracy z rządowym wsparciem. Nabór wniosków ruszy w sierpniu

Ministerstwo Rodziny, Pracy i Polityki Społecznej uruchamia pilotaż krótszego tygodnia pracy. Zainteresowane wzięciem w nim udziału firmy będą się mogły ubiegać o wsparcie finansowe ze strony rządu. Politycy Nowej Lewicy, którzy są pomysłodawcami testu tego rozwiązania, przekonują, że finalnie zyskają na nim wszyscy, zarówno pracownicy, jak i pracodawcy, a ostrzeżenia o spodziewanych problemach gospodarki są mocno przesadzone.

Partner serwisu

Instytut Monitorowania Mediów

Szkolenia

Akademia Newserii

Akademia Newserii to projekt, w ramach którego najlepsi polscy dziennikarze biznesowi, giełdowi oraz lifestylowi, a  także szkoleniowcy z wieloletnim doświadczeniem dzielą się swoją wiedzą nt. pracy z mediami.